Yeytuo

Yeytuo (Lenacapavir) is an oral antiviral medication used for long-acting HIV treatment and prevention. This overview covers its therapeutic role, common effects, and safety considerations for informed use.

Lenacapavir is primarily used in HIV therapy as part of combination regimens for treatment-experienced adults. It is also approved for pre-exposure prophylaxis (PrEP) in adults at high risk of infection. The medication works by blocking HIV replication at multiple stages, supporting viral load suppression. Patients often inquire about its role in managing treatment-resistant HIV or reducing infection risk.

Lenacapavir is designed for sustained antiviral activity, with effects lasting weeks after dosing. Common effects include gastrointestinal discomfort like nausea or diarrhea in some users. These effects are typically mild and temporary. The medication’s long-acting formulation aims to improve adherence compared to daily regimens.

Lenacapavir should be stored at room temperature away from moisture and heat. Patients with severe kidney or liver issues should discuss use with a healthcare provider. Regular medical monitoring is advised during treatment to assess efficacy and tolerability. Avoid crushing or splitting tablets unless directed.

Lenacapavir may interact with drugs that affect liver enzymes, such as certain antifungals or anticonvulsants. Combining it with strong CYP3A inducers could reduce its effectiveness. Patients taking hormonal contraceptives or statins should consult a provider to assess interaction risks. Alcohol use may exacerbate side effects like nausea.